Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.32 - $6.7 $96,944 - $195,640
29,200 Added 5.75%
536,700 $1.99 Million
Q2 2024

Aug 15, 2024

SELL
$4.82 - $9.15 $2.94 Million - $5.58 Million
-610,100 Reduced 54.59%
507,500 $3.21 Million
Q1 2024

May 07, 2024

BUY
$3.23 - $6.17 $2.13 Million - $4.07 Million
659,500 Added 143.96%
1,117,600 $6 Million
Q4 2023

Feb 14, 2024

SELL
$1.25 - $5.21 $337,875 - $1.41 Million
-270,300 Reduced 37.11%
458,100 $2.3 Million
Q3 2023

Nov 14, 2023

SELL
$1.29 - $3.1 $393,321 - $945,190
-304,900 Reduced 29.51%
728,400 $1.23 Million
Q2 2023

Aug 11, 2023

BUY
$1.53 - $6.41 $1.49 Million - $6.22 Million
970,600 Added 1548.01%
1,033,300 $2.87 Million
Q1 2023

May 16, 2023

SELL
$1.35 - $4.78 $7,290 - $25,812
-5,400 Reduced 7.93%
62,700 $114,000
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.77 $16,094 - $25,049
3,700 Added 5.75%
68,100 $345,000
Q3 2022

Nov 14, 2022

BUY
$3.65 - $6.43 $113,880 - $200,616
31,200 Added 93.98%
64,400 $320,000
Q2 2022

Aug 15, 2022

BUY
$2.68 - $6.14 $54,136 - $124,028
20,200 Added 155.38%
33,200 $124,000
Q1 2022

May 16, 2022

SELL
$5.05 - $7.53 $201,495 - $300,447
-39,900 Reduced 75.43%
13,000 $73,000
Q4 2021

Feb 14, 2022

SELL
$5.67 - $10.18 $460,404 - $826,616
-81,200 Reduced 60.55%
52,900 $322,000
Q3 2021

Nov 15, 2021

SELL
$9.17 - $14.24 $231,084 - $358,848
-25,200 Reduced 15.82%
134,100 $1.31 Million
Q2 2021

Aug 11, 2021

SELL
$13.41 - $22.4 $2.99 Million - $5 Million
-223,300 Reduced 58.36%
159,300 $2.28 Million
Q1 2021

May 17, 2021

BUY
$12.83 - $42.25 $4.91 Million - $16.2 Million
382,600 New
382,600 $9.08 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.8B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.